Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01601873 · ClinicalTrials.gov registry record · NA

Propaten Randomized Investigation on Cost-benefit and Efficacy

A NA study, sponsored by The University of Texas Health Science Center, Houston.

Terminated
Registry status
NA
Development phase
103
Enrollment target

NCT01601873 is a NA study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 103 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01601873, a NA study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.

TERMINATED
Registry status
NA
Development phase
103 participants
Enrollment target

Study Summary

The purpose for this study is to evaluate the patency and outcomes of conventional and heparin anticoagulant bonded arteriovenous grafts in patients with end stage renal disease.

Interventions

  • DEVICE PROPATEN
  • DEVICE Standard Graft

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2012-11-09
Est. Completion 2018-06-30
Phase NA

What the Registry Record Tells You About NCT01601873

The ClinicalTrials.gov registry entry for NCT01601873 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which PROPATEN is the first listed.

NCT01601873 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01601873 about?

NCT01601873 is a clinical study titled "Propaten Randomized Investigation on Cost-benefit and Efficacy". The purpose for this study is to evaluate the patency and outcomes of conventional and heparin anticoagulant bonded arteriovenous grafts in patients with end stage renal disease.

What is the current status of trial NCT01601873?

This trial is currently terminated. It is a NA study. The enrollment target is 103 participants. The study started on 2012-11-09. Estimated completion is 2018-06-30.

What interventions are being tested in trial NCT01601873?

The interventions under investigation include: PROPATEN (DEVICE), Standard Graft (DEVICE).

Who is sponsoring clinical trial NCT01601873?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.